Wall Street set for muted open as markets await Fed verdict; Apple, Nvidia falter
Reuters
Wall Street's main indexes were on track for a subdued open on Wednesday, as losses in tech heavyweights Apple and Nvidia kept broader gains in check and investor attention turned to the U.S. Federal Reserve's interest-rate decision, due later in the day.
Markets widely expect the central bank to hold its lending rate steady in its decision, expected at 2 p.m. ET.
"Without clarity on the macro impact of a range of government policies, primarily tariffs, but also on tax policy and the labor market impact of immigration policy, we think it's fair to expect limited guidance from the Fed today," Goldman Sachs economists said in a note.
Meanwhile, shares of semiconductor firms and related equipment makers advanced in premarket trading after Dutch firm ASML ASML.AS reported fourth-quarter bookings of 7.09 billion euros ($7.39 billion), a number far exceeding expectations.
KLA Corp KLAC.Orose 2.1%, Applied Materials AMAT.Owas up 2.7%, Lam Research LRCX.Ogained 2.8% and Micron Technology MU.Oadded 1.5%.
Invest wisely: Best online brokers
Nvidia NVDA.O dropped 2% after gaining close to 9% on Tuesday. Its shares were hammered on Monday, after Chinese startup DeepSeek launched AI models it said were cost-effective and ran on less advanced chips.
What is DeepSeek?:How a small Chinese startup shook up the AI sector
Apple AAPL.O shed 1.8% after brokerage Oppenheimer downgraded its rating to "perform" from "outperform". The iPhone maker is scheduled to report quarterly earnings later this week.
The Nasdaq .IXIC jumped 2% in the last session, while the S&P 500 .SPX rose close to 1% as Nvidia NVDA.O and other artificial intelligence-linked tech shares recovered somewhat from the steep losses suffered earlier in the week.
Markets have been on edge due to worries around U.S. President Donald Trump's proposed tariffs, which could exacerbate inflationary pressures and slow rate cuts.
Trump still plans to make good on his promise to impose tariffs on Canada and Mexico on Saturday, White House press secretary Karoline Leavitt said on Tuesday.
Point72 Asset Management's founder Steven Cohen said he expects the stock market to reach a peak soon, amid inflationary pressures and uncertainties around Trump's policies on tariffs and immigration.
The December reading of the personal consumption expenditures price index, a crucial metric in assessing the inflation trajectory, is due on Friday.
At 8:27 a.m. ET, Dow E-minis 1YMcv1 were down 71 points, or 0.16%, S&P 500 E-minis EScv1 were down 12.25 points, or 0.2%, and Nasdaq 100 E-minis NQcv1 were up 8 points, or 0.04%.
Among earnings, T-Mobile TMUS.O added 6.3% after the company forecast stronger-than-expected annual subscriber growth driven by increased demand for its affordable premium 5G plans.
Danaher DHR.Nshed 5.7% after the life sciences company missed estimates for fourth-quarter profit, due to soft demand for tools and services used in drug development by its biotech and pharmaceutical clients.
Earnings from Magnificent 7 stocks Microsoft MSFT.O, Facebook-parent Meta META.O and Tesla TSLA.O are expected after markets close.
Cybersecurity and cloud services company F5 FFIV.O jumped 13.5% after forecasting second-quarter revenue above estimates and posting a first-quarter revenue beat.
Chipmaker Qorvo QRVO.O lost 3.7% after it reported lower third-quarter revenue.
($1 = 0.9628 euros)
Reporting by Shashwat Chauhan and Sukriti Gupta in Bengaluru; Editing by Shounak Dasgupta, Arun Koyyur and Pooja Desai
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
What You Need to Know Ahead of Ross Stores' Earnings Release
With a market cap of $42.8 billion, Ross Stores, Inc. (ROST) operates off-price retail apparel and home fashion stores under the Ross Dress for Less and dd's DISCOUNTS brands in the United States. Headquartered in Dublin, California, the company offers apparel, accessories, footwear, and home fashions products. ROST is expected to report its Q2 earnings on Thursday, Aug. 28. Ahead of the event, analysts expect ROST to report a profit of $1.53 per share, down 3.8% from a profit of $1.59 per share reported in the year-ago quarter. It has exceeded analysts' earnings estimates in each of the past four quarters, which is notable. More News from Barchart 2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025 UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For the current year, analysts expect ROST to report EPS of $6.23, down 1.4% from $6.32 in fiscal 2024. However, its EPS is likely to rise 9% year over year to $6.79 in FY2026. Over the past year, ROST shares surged 4%, underperforming the S&P 500 Index's ($SPX) 17.3% gains and the Consumer Discretionary Select Sector SPDR Fund's (XLY) 22.9% returns over the same time frame. On Jul. 2, shares of Ross Stores climbed more than 1% after Jefferies Financial Group Inc. (JEF) upgraded the stock from a 'Hold' to a 'Buy' rating. The firm also raised its price target to $150, citing improved traffic trends, solid inventory management, and a favorable off-price retail environment as key catalysts for potential upside in the stock. The consensus opinion on ROST stock is highly upbeat, with an overall 'Strong Buy' rating. Out of the 19 analysts covering the stock, 15 recommend a 'Strong Buy' and four recommend a 'Hold.' Its mean price target of $154.53 indicates a robust 11.1% upside potential from current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Dollar Tree Earnings Preview: What to Expect
Dollar Tree, Inc. (DLTR) is a major U.S. discount retailer headquartered in Virginia, operating over 9,000 stores under the Dollar Tree and Dollar Tree Canada brands. With a market cap of $24 billion, the company offers a wide range of consumables, seasonal goods, and general merchandise through its physical locations and bulk e-commerce platform, supported by a nationwide logistics network. The company is expected to announce its fiscal Q2 2025 earnings results on Wednesday, Sept. 3. Ahead of this event, analysts expect the company to report an adjusted EPS of $0.36, down 46.3% from $0.67 in the year-ago quarter. It has surpassed Wall Street's earnings estimates in two of the last four quarters while missing on two other occasions. More News from Barchart 2 Recession-Proof Dividend Stocks to Buy for the Second Half of 2025 UnitedHealth Stock Spirals Lower Again. Don't Buy the Dip. Auto Revenue Keeps Plunging at Tesla. Should You Buy the TSLA Stock Dip or Run Far Away? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For fiscal 2025, analysts expect the discount store chain to report an adjusted EPS of $5.43, up 6.5% from $5.10 in fiscal 2024. In addition, adjusted EPS is anticipated to grow 15.1% year-over-year to $6.25 in fiscal 2026. DLTR shares have climbed 10.2% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 17.3% gain but surpassing the Consumer Staples Select Sector SPDR Fund's (XLP) 4.6% return over the same period. On July 21, shares of Dollar Tree gained more than 2% following an upgrade from Barclays plc (BCS), which raised its rating on the stock to 'Overweight' from 'Equal Weight.' The firm also lifted its price target to $120, citing improved fundamentals and growing confidence in the company's turnaround strategy. Barclays highlighted Dollar Tree's focus on reaccelerating growth through store remodels, pricing flexibility with its Dollar Tree Plus format, and the recent divestiture of its underperforming Family Dollar segment as key catalysts. The upgrade reflects optimism around the retailer's potential to expand margins, drive stronger traffic, and enhance shareholder value in the coming quarters. Analysts' consensus view on Dollar Tree's stock is cautiously optimistic, with a "Moderate Buy" rating overall. Among 23 analysts covering the stock, eight recommend "Strong Buy," 13 suggest "Hold," one gives "Moderate Sell," and one 'Strong Sell.' DLTR currently trades above its average analyst price target of $99.28. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data